321 related articles for article (PubMed ID: 34818767)
41. COVID-19 associated mucormycosis surge: A review on multi-pathway mechanisms.
Pourazizi M; Hakamifard A; Peyman A; Mohammadi R; Dehghani S; Tavousi N; Hosseini NS; Azhdari Tehrani H; Abtahi-Naeini B
Parasite Immunol; 2024 Jan; 46(1):e13016. PubMed ID: 37846902
[TBL] [Abstract][Full Text] [Related]
42. Perturbations of immune landscape in COVID-19 associated mucormycosis.
Desai N; Pradhan V; Chougule D; Tiwari S; Mandke C; Yadav RM; Athvale A; Kawle J; Pai V; Pawaskar S; Kharkar H; Bhosale S; Parab A; Ansari S; Kumar KH; Mhashal S; Redkar N; Madkaikar M
Mycoses; 2023 Mar; 66(3):226-236. PubMed ID: 36380699
[TBL] [Abstract][Full Text] [Related]
43. A case control investigation of COVID-19 associated mucormycosis in India.
Anand T; Mukherjee A; Satija A; Velamuri PS; Singh KJ; Das M; Josten K; Yadav PD; Sahay RR; Keche AY; Nagarkar NM; Gupta P; Himanshu D; Mistry SN; Patel JD; Rao P; Rohatgi S; Ghosh S; Hazra A; Kindo AJ; Annamalai R; Rudramurthy SM; Singh MP; Shameem M; Fatima N; Khambholja JR; Parikh S; Madkaikar M; Pradhan VD; Kataria S; Sharma P; Panda S;
BMC Infect Dis; 2022 Nov; 22(1):856. PubMed ID: 36384482
[TBL] [Abstract][Full Text] [Related]
44. COVID-19-associated mixed mold infection: A case report of aspergillosis and mucormycosis and a literature review.
Benhadid-Brahmi Y; Hamane S; Soyer B; Mebazaa A; Alanio A; Chousterman B; Bretagne S; Dellière S
J Mycol Med; 2022 Mar; 32(1):101231. PubMed ID: 34864498
[TBL] [Abstract][Full Text] [Related]
45. Serum iron indices in COVID-19-associated mucormycosis: A case-control study.
Kumar H M; Sharma P; Rudramurthy SM; Sehgal IS; Prasad KT; Pannu AK; Das R; Panda NK; Sharma N; Chakrabarti A; Agarwal R; Muthu V
Mycoses; 2022 Jan; 65(1):120-127. PubMed ID: 34743358
[TBL] [Abstract][Full Text] [Related]
46. COVID-19-associated Mucormycosis: A clinico-epidemiological study.
Chakravarty J; Gupta MK; Tilak R; Kumar R; Maurya RP; Kumar N; Aggarwal SK; S S; Sharma NK; Dhiman NK; Chaubey M; Singh V; Verma A; Banerjee T; Agrawal NK; Prasad RS
J Diabetes Complications; 2022 Sep; 36(9):108284. PubMed ID: 35987108
[TBL] [Abstract][Full Text] [Related]
47. The cross-talk between mucormycosis, steroids and diabetes mellitus amidst the global contagion of COVID-19.
Dwivedi S; Choudhary P; Gupta A; Singh S
Crit Rev Microbiol; 2023 May; 49(3):318-333. PubMed ID: 35324372
[TBL] [Abstract][Full Text] [Related]
48. The Second COVID-19 Wave Is a Tsunami With Aftershocks: Mucormycosis Ire as Seen in a Tertiary Care Hospital in Uttarakhand, India.
Raina D; Rohilla R; Patwal S; Pandita A
Cureus; 2023 Oct; 15(10):e47358. PubMed ID: 38021725
[TBL] [Abstract][Full Text] [Related]
49. COVID-19-associated-mucormycosis: possible role of free iron uptake and immunosuppression.
Tabassum T; Araf Y; Moin AT; Rahaman TI; Hosen MJ
Mol Biol Rep; 2022 Jan; 49(1):747-754. PubMed ID: 34709573
[TBL] [Abstract][Full Text] [Related]
50. The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries.
Hoenigl M; Seidel D; Carvalho A; Rudramurthy SM; Arastehfar A; Gangneux JP; Nasir N; Bonifaz A; Araiza J; Klimko N; Serris A; Lagrou K; Meis JF; Cornely OA; Perfect JR; White PL; Chakrabarti A;
Lancet Microbe; 2022 Jul; 3(7):e543-e552. PubMed ID: 35098179
[TBL] [Abstract][Full Text] [Related]
51. As the virus sowed, the fungus reaped! A comparative analysis of the clinico-epidemiological characteristics of rhino-orbital mucormycosis before and during COVID-19 pandemic.
Muraleedharan M; Panda NK; Angrish P; Arora K; Patro SK; Bansal S; Chakrabarti A; Rudramurthy SM; Bakshi J; Mohindra S; Gupta R; Virk RS; Verma RK; Ramavat AS; Nayak G
Mycoses; 2022 May; 65(5):567-576. PubMed ID: 35289000
[TBL] [Abstract][Full Text] [Related]
52. COVID Induced Functional Exhaustion and Persistently Reduced Lymphocytes as Vital Contributing Factors for Post-COVID Rhino-orbital and Cerebral Mucormycosis in Patients with Diabetes: Report from the Indian Sub-continent.
Bhargava D; Ahirwal R; Dubey S; Gurjar P; Pandey A; Beena S; Koneru G
Head Neck Pathol; 2022 Sep; 16(3):645-650. PubMed ID: 34751896
[TBL] [Abstract][Full Text] [Related]
53. A Novel Study of Correlation of Lipid Parameters with Clinical Profile, Staging and Onset of Rhino Orbito Cerebral Mucormycosis Covid 19 Pandemic.
V V; St K
J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443508
[TBL] [Abstract][Full Text] [Related]
54. The risk of cutaneous mucormycosis associated with COVID-19: A perspective from Pakistan.
Asri S; Akram MR; Hasan MM; Asad Khan FM; Hashmi N; Wajid F; Ullah I
Int J Health Plann Manage; 2022 Mar; 37(2):1157-1159. PubMed ID: 34476830
[TBL] [Abstract][Full Text] [Related]
55. Risks of mucormycosis in the current Covid-19 pandemic: a clinical challenge in both immunocompromised and immunocompetent patients.
Monika P; Chandraprabha MN
Mol Biol Rep; 2022 Jun; 49(6):4977-4988. PubMed ID: 35107737
[TBL] [Abstract][Full Text] [Related]
56. Comparative Evaluation of COVID-19 Associated Mucormycosis (CAM) and Non-COVID-19-associated Mucormycosis (non-CAM).
Oruc E; Gulen TA; Turunc T; Ekici NY; Unal N
J Coll Physicians Surg Pak; 2023 Feb; 33(2):153-157. PubMed ID: 36797623
[TBL] [Abstract][Full Text] [Related]
57. The hospitalization rate and clinical characteristics of mucormycosis prior and during COVID-19 pandemic: A single-center study.
Estakhr M; Ghotbi Z; Rostamihosseinkhani M; Hooshmandi E; Janipour M; Ostovan VR; Fadakar N; Bazrafshan H; Bahrami Z; Rahimi-Jaberi A; Poursadeghfard M; Nazeri M; Kouhi P; Petramfar P; Izadi S; Barzegar Z; Nikzadeh E; Sasannia S; Arsang-Jang S; Tabrizi R; Khademi B; Kohandel-Shirazi M; Salehi MS; Ashjazadeh N; Khademi B; Ashraf MJ; Eilami O; Roudgari A; Moghaddami M; Zomorodian K; Badali H; Borhani-Haghighi A
J Infect Dev Ctries; 2023 Jun; 17(6):791-799. PubMed ID: 37406065
[TBL] [Abstract][Full Text] [Related]
58. Fostering a deeper understanding of COVID-19-associated mucormycosis - A commentary on "The mucormycosis coinfection in the context of global COVID-19 outbreak: A fatal addition to the pandemic spectrum" (Int. J. Surg. 2021:106031).
MohanaSundaram A; Sathanantham ST; Chinchole V; Patil B; Velayutham R
Int J Surg; 2021 Oct; 94():106110. PubMed ID: 34534704
[No Abstract] [Full Text] [Related]
59. Epidemiology, clinical presentation and management of COVID-19 associated mucormycosis: A single centre experience from Pune, Western India.
Dravid A; Kashiva R; Khan Z; Bande B; Memon D; Kodre A; Mane M; Pawar V; Patil D; Kalyani S; Raut P; Bapte M; Saldanha C; Chandak D; Patil T; Reddy S; Bhayani K; Suresh L; Dillibabu V; Srivastava S; Khandelwal S; More S; Shakeel A; Pawar M; Nande P; Harshe A; Kadam S; Hallikar S; Kamal N; Andrabi D; Bodhale S; Raut A; Chandrashekhar S; Raman C; Mahajan U; Joshi G; Mane D
Mycoses; 2022 May; 65(5):526-540. PubMed ID: 35212032
[TBL] [Abstract][Full Text] [Related]
60. Is Mucormycosis an inevitable complication of Covid-19 in India?
Bhogireddy R; Krishnamurthy V; Jabaris S SL; Pullaiah CP; Manohar S
Braz J Infect Dis; 2021; 25(3):101597. PubMed ID: 34289382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
